Hookipa Pharma INC DEF 14A proxy statements

HOOKIPA Pharma Inc. is seeking stockholder approval for the sale of its Hepatitis B and HIV programs to Gilead Sciences for up to $10 million, followed by the company's liquidation and dissolution, with an estimated per-share distribution of $1.28 to $1.72 to stockholders.

HOOKIPA Pharma Inc. announced an agreement to sell its HB-400 and HB-500 programs to Gilead Sciences, Inc. for up to $10 million, with plans to dissolve the company and distribute remaining cash to stockholders following the transaction.

Hookipa Pharma Inc. has entered into an agreement to sell its HB-400 and HB-500 programs to Gilead Sciences for up to $10 million and intends to dissolve the company pending stockholder approval.

HOOKIPA Pharma and Poolbeg Pharma provide an update on their non-binding discussions regarding a potential acquisition of Poolbeg by HOOKIPA, including Gilead's intended participation in a concurrent fundraise.

HOOKIPA Pharma and Poolbeg Pharma provide an update on their potential combination, with Gilead Sciences indicating support and HOOKIPA announcing a $30 million+ private placement fundraise.

HOOKIPA Pharma and Poolbeg Pharma are in preliminary talks for HOOKIPA to acquire Poolbeg in an all-share transaction, aiming to create a strong biopharmaceutical company.

Hookipa Pharma Inc. is holding its annual meeting on June 17, 2024, to vote on director elections, auditor ratification, an increase in authorized shares, and a potential reverse stock split.

HOOKIPA Pharma is asking stockholders to approve an increase in authorized shares and a reverse stock split at its upcoming annual meeting.